Prostate Cancer Clinical Trials in Orlando, Florida

7 studies are recruiting for prostate cancer in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Advent Health, Orlando, Florida

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

   To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

   Stage

   Not phased

   Ages

   18 and older

   Site

   AdventHealth, Orlando, Florida

   Locations

   23 in total

   Run by

   Axonics, Inc.

   See if you can join NCT06511141 on ClinicalTrials.gov

3. A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

   This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further sp…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Orlando, Florida

   Locations

   26 in total

   Run by

   AstraZeneca

   See if you can join NCT07192614 on ClinicalTrials.gov

4. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

   The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   AdventHealth, Orlando, Florida

   Locations

   95 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06855277 on ClinicalTrials.gov

5. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

   This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   AdventHealth, Orlando, Florida

   Locations

   81 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06780670 on ClinicalTrials.gov

6. A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

   The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors. The main objectives of this study are : * To Determine the maximum tolerated dose (MTD) and recommended dose for expa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists & Research Institute, Orlando, Florida

   Locations

   7 in total

   Run by

   Phrontline Biopharma

   See if you can join NCT07181473 on ClinicalTrials.gov

7. Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

   To evaluate a community-based outreach initiative for screening, diagnosis, and treatment of breast, lung, and prostate cancers in underserved adults using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) implementation science framework.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Adventhealth, Orlando, Florida

   Run by

   AdventHealth

   See if you can join NCT07231159 on ClinicalTrials.gov